Crikey!
This article was originally published in The Tan Sheet
Executive Summary
"The Antidote," marketed by London-based 1Biologicalmiracle.com, is the target of a Jan. 16 FDA warning letter for unapproved drug claims. The single-dose liquid product is marketed as an anti-microbial protein extract derived from crocodile blood. FDA is troubled by claims the product "really is the all inclusive miracle that will kill all viruses and bacteria your body can throw at it" and "even serious infectious diseases such as cancer, AIDS, SARS and many other life-threatening diseases can be helped by the power of the Antidote." The agency additionally is concerned that the Antidote is offered for sale to U.S. citizens...
You may also be interested in...
NAD’s not buying “The Antidote”
Advertising for BiologicalMiracle.com's "The Antidote" will be referred to FDA for "possible law enforcement action," the National Advertising Division of the Council for Better Business Bureaus announces July 6. Product claims such as "kills all known deadly viruses and bacteria in the body" were brought to NAD's attention through its routine monitoring program. BiologicalMiracle "failed to submit a substantive response or provide any evidence to substantiate health claims" made for the product, the Council for Better Business Bureaus division states. The product was the target of an FDA Warning Letter in early 2004 (1"The Tan Sheet" Feb. 2, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.